AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03122860
Drug: SM04690
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthcare professional-administered intra-articular injection performed once on Day 1 of the study
Trial: NCT01600274
Drug: Dienogest-Ethinyl Estradiol (test product)
RxNorm normalized name: dienogest / ethinyl estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet of Test
Trial: NCT01600274
Drug: Dienogest-Ethinyl Estradiol (reference product)
RxNorm normalized name: dienogest / ethinyl estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet of Reference
Trial: NCT00626366
Drug: Omnipaque 240 Contrast Solution
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will spray 2-4 drops of half-strength Omnipaque 240 mgI/mL into each nare. Each spray is approximately 0.1 ml.
Trial: NCT00626366
Drug: Omnipaque 240 mg I/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will place two drops of half-strength Omnipaque 240 mg I/mL intranasally to each nose. Each drop is approximately 1 ml.
Trial: NCT01253174
Drug: EE 0.03 mg/DRSP 3 mg (Yasmin, BAY86-5131)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral administration of 1 coated tablet SH T470FA (Yasmin, film-coated tablets with ethinylestradiol (EE) as free steroid), containing 0.030 mg EE + 3 mg drospirenone (DRSP)
Trial: NCT01253174
Drug: EE 0.03mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE30/DRSP/L-5-MTHF Ca)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral administration of 1 coated tablet SH T04532A (film-coated tablet with ethinylestradiol (EE) as clathtrate), containing 0.030 mg EE + 3 mg drospirenone (DRSP) + 0.451 mg Metafolin
Trial: NCT01253174
Drug: L-5-MTHF Ca 0.451 mg (Metafolin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral administration of 1 coated tablet SH T04532C, containing 0.451 mg Metafolin
Trial: NCT02055079
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed oral dose of 3 mg placebo (blinded) once weekly for 24 months.
Trial: NCT00001255
Drug: ADA PBSC
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06153784
Drug: Hydroxyurea and Thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Evaluation of hydroxyurea and thalidomide combination use in beta-thalassemia patients
Trial: NCT04655040
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100milligram (mg) tablet taken orally in period 1 and period 2
Trial: NCT00375050
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02244346
Drug: Secotex®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02395263
Drug: Yuxintine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01071239
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy administered as a part of the HSCT conditioning regimen.
Trial: NCT01000649
Drug: FE 202158 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FE 202158 at dose 1.25 ng/kg/min infused.
Trial: NCT01000649
Drug: FE 202158 3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FE 202158 at dose 3.75 ng/kg/min infused.
Trial: NCT03076944
Drug: UltraEZ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylaxis, apply uniformly on the teeth, wait 15 minutes, remove the gel from the teeth with cotton and abundant water.
Trial: NCT03076944
Drug: Enamelast
RxNorm normalized name: Enamelast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylaxis; dry the teeth; apply uniformly on the teeth with a thin layer.
Trial: NCT01807650
Drug: Oleogel-S10, non-adhesive wound dressing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 cm or 100 mg Oleogel-S10 per cm2 wound area (corresponds to thickness of approximately 1 mm or 0.04 inch) every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28
Trial: NCT02761317
Drug: standard preparation (2L PEG-ELS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects who are randomized into group A will receive standard bowel preparation (2L PEG-ELS) on the same-day of procedure.
Trial: NCT00600990
Drug: GW597599
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00838799
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TID, capsules, 14 weeks.
Trial: NCT03116191
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 weeks of repeated administration of Placebo to the patients of nocturia
Trial: NCT01537497
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One single oral dose of placebo will be administered as a powder-in-capsule in the fasting state in the AM.
Trial: NCT02732132
Drug: Propofol and Fentanyl
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This group was injected intravenous fentanyl 1 mcg/kg, and two minutes later, propofol 1 mg/kg was given intravenously before the start of endoscopy.
Trial: NCT00904202
Drug: Placebo Capsules + Placebo Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).
Trial: NCT00904202
Drug: Placebo capsules + Lidoderm®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).
Trial: NCT04199767
Drug: 20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be assigned to receive regular insulin either 20 or 40 IU administered through an intranasal nebulizer-like device.
Trial: NCT04199767
Drug: 40 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be assigned to receive regular insulin either 40 or 20 IU administered through an intranasal nebulizer-like device.
Trial: NCT02073097
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV (750mg/m\^2)
Trial: NCT02073097
Drug: Doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV (50mg/m\^2)
Trial: NCT04495816
Drug: Omega-3 Fatty Acid Supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomized to this arm will be instructed to take two of the softgels they received per day for 6 weeks. They will receive softgels containing 1,000 mg of omega-3 fatty acid. 1000 mg of omega-3 fatty acid blend including 683 mg Eicosapentaenoic Acid and 252 mg Docosahexaenoic Acid
Trial: NCT04495816
Drug: Placebo/Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to this arm will also be instructed to take two of the softgels they received per day for 6 weeks. They will receive placebo softgels that are indistinguishable from those containing fish oil.
Trial: NCT00001579
Drug: Ethynyluracil
RxNorm normalized name: 5-Ethynyluracil
DrugBank: Eniluracil (DB03516)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00001579
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02363049
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00004784
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01168310
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation Solution
Trial: NCT01885559
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.
Trial: NCT01881997
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl Intramuscular (IM), 1ugm/kg, x1
Trial: NCT01881997
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM normal saline
Trial: NCT02318810
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive saline
Trial: NCT01342497
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets, dosing 3 times daily, 12 weeks
Trial: NCT01787097
Drug: Symbicort® total dose 400ug/12ug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symbicort® is combination of formoterol 400ug and budesonide 12ug. Single dose
Trial: NCT01787097
Drug: Symbicort® total dose 800ug/24ug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symbicort® is combination of formoterol 800ug and budesonide 24ug. Single dose
Trial: NCT00949884
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo oral tablets once daily for two weeks
Trial: NCT01217736
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose, tablet
Trial: NCT01527487
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be given as an IV infusion (600 mg/m2) on Day 1 of each treatment cycle over approximately 30 minutes, or per institutional standard.
Trial: NCT00242281
Drug: APC-111 MP Tablet, 775 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00125021
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given twice a day for 14 days followed by 7 days of no capecitabine (1 cycle is 21 days).
Trial: NCT03070301
Drug: LEE011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEE011 200 mg daily
Trial: NCT04692766
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline (0.9% Sodium Chloride solution for Injection), 5 mL in a polypropylene ampoule, 10 ampoules per labeled package
Trial: NCT01210495
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo \[tablet, 1 mg, 5 mg\] will be given twice daily \[BID\] with continuous dosing; duration is approximately 3-6 months; starting dose is 5 mg BID
Trial: NCT00648934
Drug: Topamax® Sprinkle Capsules 25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25mg, single dose fed
Trial: NCT00751257
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identically appearing placebo capsules, packaged in an N-acetylcysteine slurry so that placebo has similar odor as active NAC capsules
Trial: NCT02193139
Drug: WL8713, 6 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02193139
Drug: WL8713, 12 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02193139
Drug: WL8713, 18 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02193139
Drug: WL8713, 24 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02193139
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01471717
Drug: INX-08189 50 mg QD X 5 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 1: Subjects will begin administration of INX-08189 50 mg QD on Study Day 0. Dosing will occur each morning for 5 days after a fast of at least 8 hours prior to each dose on Study Days 0 through 4. INX-08189 will be administered with water, and subjects will remain fasting for 2 hours following each dose.
Trial: NCT01471717
Drug: INX-08189 / Victrelis 800 mg TID X three days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 1: INX-08189 50 mg QD will be administered concurrently with Victrelis 800 mg TID for 3 additional days (Study Days 5 through 7)
Trial: NCT01471717
Drug: Victrelis 800 mg TID x 3 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Cohort 2, subjects will begin administration of Victrelis 800 mg TID on the morning of Study Day 0. Victrelis will be administered with water and food with doses at least 7 hours apart. Victrelis 800 mg TID will be administered for a total of 3 days (Study Days 0 through 2).
Trial: NCT01471717
Drug: Victrelis 800 mg TID with INX-08189 50 mg QD
RxNorm normalized name: thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Victrelis 800 mg TID will be administered concurrently with INX-08189 50 mg QD for 5 additional days (Study Days 3 through 7).
Trial: NCT01471717
Drug: Placebo with Victrelis 800 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During combination dosing with INX-08189 and Victrelis, each morning dose will start with INX-08189 or placebo after at least an 8 hour fast, followed by a 2 hour fast with the first Victrelis dose of the day then administered with food.
Trial: NCT01471717
Drug: Cohort 2: Victrelis 800 mg with Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During combination dosing with INX-08189 and Victrelis, each morning dose will start with INX-08189 or placebo after at least an 8 hour fast, followed by a 2 hour fast with the first Victrelis dose of the day then administered with food.
Trial: NCT03610685
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given daily for 2 weeks
Trial: NCT03610685
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given daily for 2 weeks
Trial: NCT01139190
Drug: PL3100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT01139190
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT02293395
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ASA 100 mg enteric-coated tablet once daily orally.
Trial: NCT01529008
Drug: Core decompression/PREOB® implantation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will undergo a core decompression under general anesthesia combined with the implantation of PREOB® into the necrotic lesion (single administration).
Trial: NCT01529008
Drug: Core decompression/placebo implantation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will undergo a core decompression under general anesthesia combined with the implantation of placebo into the necrotic lesion (single administration).
Trial: NCT00147901
Drug: FCCam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After an initial subcutaneous dose escalation of alemtuzumab over 2 days, 30 mg alemtuzumab s.c., cyclophosphamide 200 mg/m2 i.v. and 25 mg/m2 fludarabine i.v. were administered on three consecutive days. Treatment was repeated after 28 days for up to six cycles
Trial: NCT00224770
Drug: MIS+Cathflo Activase (drug)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MIS+Cathflo Activase (drug): The intervention is a comparison of the safety and preliminary effectiveness of investigational minimally invasive surgery to place a catheter into an intracerebral hemorrhage blood clot and subsequent administration in sequential tiers of 0.3 or 1.0mg of rt-PA, CathFlo® through the catheter once every eight hours for up to 72 hours, in addition to best medical care.
Trial: NCT01238718
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline
Trial: NCT03588078
Drug: APR-246
RxNorm normalized name: PrameGel Reformulated Apr 2012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azacitidine at maximum tolerated dose. APR246 at the Dose limited Toxicity (DLT) dose
Trial: NCT00602290
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pills will be taken in combination with the active pills. Participants will initially take 1 capsule twice per day, which will be increased to a maximum of 16 capsules twice per day matching methylphenidate, and 1-3 capsules matching citalopram. After Visit 11, placebo dosage will be gradually reduced over 2 weeks until participants are no longer taking any capsules.
Trial: NCT02229929
Drug: Part A: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A: Single i.v. dose of Placebo administered after each dialysis session over a 1 week treatment period (3 times per week)
Trial: NCT02229929
Drug: Part A: CR845 0.5 mcg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A: Single i.v. dose of CR845 administered after each dialysis session over a 1 week treatment period (3 times per week)
Trial: NCT02229929
Drug: Part A: CR845 1.0 mcg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A: Single i.v. dose of CR845 administered after each dialysis session over a 1 week treatment period (3 times per week)
Trial: NCT02229929
Drug: Part A: CR845 2.5 mcg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A: Single i.v. dose of CR845 administered after each dialysis session over a 1 week treatment period (3 times per week)
Trial: NCT02229929
Drug: Part B: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part B: Single i.v. dose of Placebo administered after each dialysis session over a 2 week treatment period (3 times per week)
Trial: NCT02229929
Drug: Part B: CR845 1.0 mcg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part B: Single i.v. dose of CR845 administered after each dialysis session over a 2 week treatment period (3 times per week)
Trial: NCT00799331
Drug: AZD5985
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral suspension. Single oral doses of AZD5985 starting with 4 mg and subsequently with up to 3 dose escalations will be administered not exceeding AstraZeneca pre-defined upper exposure limits.
Trial: NCT02071810
Drug: BIA 9-1067
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00799331
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral suspension.
Trial: NCT01537068
Drug: Desvenlafaxine
RxNorm normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desvenlafaxine oral dose ranging from 50 to 100 mg/day
Trial: NCT01537068
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo pills
Trial: NCT04245722
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lympho-conditioning agent
Trial: NCT01742585
Drug: ASP1585
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01742585
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00458510
Drug: Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: treatment of up to 4 episodes of pain per day
Trial: NCT01312714
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 tablets of 1000 IU daily for 26 weeks
Trial: NCT00951834
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00409747
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03858556
Drug: Herbal medicine
RxNorm normalized name: Herbal medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
Trial: NCT00383695
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02783599
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT02767661
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine, 500mg, orally three times daily (continuously)
Trial: NCT02767661
Drug: Aromatase Inhibitor
RxNorm normalized name: Aromatase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase Inhibitor (Anastrozole, 1mg, orally once daily or Letrozole, 2.5mg, orally once daily or Exemestane , 25mg, orally once daily)
Trial: NCT00839085
Drug: Vit C (Ascorbic Acid)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vit C 25 mg/ kg
Trial: NCT02451072
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules containing mannitol looking identical to LSD per os
Trial: NCT04471298
Drug: Qishenyiqi dripping pills, 9 bags
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 28 consecutive days
Trial: NCT04471298
Drug: Qishenyiqi dripping pills, 12 bags
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 28 consecutive days
Trial: NCT04471298
Drug: Qishenyiqi dripping pills placebo, 6 bags
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 28 consecutive days
Trial: NCT04471298
Drug: Qishenyiqi dripping pills placebo, 9 bags
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 28 consecutive days